Breadcrumb Home News & Events News & Events News July 2022 Meetings IMPAACT at International Workshop on HIV Pediatrics 2022 and AIDS 2022 July 2022 Announcements JIAS Special Issue: ‘Approaches to enhance and accelerate investigation of new HIV drugs in pregnancy’ April 2022 Announcements The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the publication of results from IMPAACT P1093 in the May 2022 edition of The Lancet HIV. Search Enter a search term. Filter Topics AllAnnouncementsMeetingsStudy Results Date All2022202120202019201820162014 Sort Date AscDate Desc Submit Search Showing 15 news items. February 2022 Study Results IMPAACT Shares Study Results in CROI 2022 Oral Presentations February 2022 Study Results IMPAACT P1107 Team Presents First Known Case of a Woman with HIV Remission February 2022 Study Results IMPAACT Shares Study Results at CROI 2022 Poster Presentations July 2021 Study Results IMPAACT 2019 Results Released June 2020 Study Results IMPAACT P1093 Informs FDA Decision to Approve First-ever Dolutegravir Dispersible Tablet for Treatment of Children living with HIV March 2020 Study Results IMPAACT 2001 Primary Results Released March 2020 Study Results IMPAACT 2010 Primary Results Released March 2020 Study Results IMPAACT 2009 PK Results Released December 2019 Study Results Results from P1104s published in Clinical Infectious Diseases October 2019 Study Results Primary results from the IMPAACT P1078/TB APPRISE study published Pagination Current page 1 Page 2 Next page Next
July 2022 Announcements JIAS Special Issue: ‘Approaches to enhance and accelerate investigation of new HIV drugs in pregnancy’
April 2022 Announcements The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the publication of results from IMPAACT P1093 in the May 2022 edition of The Lancet HIV.
February 2022 Study Results IMPAACT P1107 Team Presents First Known Case of a Woman with HIV Remission
June 2020 Study Results IMPAACT P1093 Informs FDA Decision to Approve First-ever Dolutegravir Dispersible Tablet for Treatment of Children living with HIV
